Skip to main content

Table 2 Descriptive parameters of the resistant patients

From: Predictors of dopamine agonist resistance in prolactinoma patients

SexBaseline PRL
(μg/l)
Age at diagnose (range in years)Symptoms (*)Mass effectsTumour classificationTumour volume (cm3)Cystic/
Necrotic/
hemorragic component
SurgerySclerosis
Man668.6720–30Sexual dysfunctionHeadache/
Dizziness
Macroadenoma3.34YesYesYes
Woman126.920–30Menstrual disturbancesNoneMacroadenoma3.33YesNo/
Woman77,220–30Menstrual dysfunction + galactorrheaVisual defectsMicroadenomaNot knownNot knownYesNo
Man1058.350–60NoneHeadache/
Dizziness
Macroadenoma6.93YesYesYes
Man230.6560–70Sexual dysfunctionHeadache/
Dizziness
Macroadenoma2.041NoNo/
Man253.7730–40Sexual dysfunctionNoneMacroadenoma1.23YesYesYes
Man332.4320–30Menstrual dysfunctionNoneMacroadenoma41.36NoYesYes
Woman2582.360–70NoneVisual defectsMacroadenoma2.65NoNo/
Woman131.050–60Menstrual dysfunctionNoneMicroadenomaNot knownNot kownYesYes
Woman90.1940–50Menstrual dysfunctionNoneMacroadenomaNot knownYesNo/
Woman162.020–30Menstrual dysfunction + galactorrheaNoneMacroadenomaNot knownYesNo/
  1. (*) Sexual dysfunction: Decreased libido + Erectile disorder; Menstrual disturbance: Amenorrhea + Infertility